AMRX: Amneal Pharmaceuticals Inc Company Value to Net Income

Corporate emblem and logo of Amneal Pharmaceuticals, Inc. (AMRX)

Amneal Pharmaceuticals (AMRX) is combating market pressure on generics by pivoting toward the complex biosimilars segment. The ability to develop hard-to-replicate drugs allows the company to maintain high margins. The current P/E multiple helps identify pricing manipulations, while the 54.80 value reflects the metric's balance. This chart confirms growth potential driven by expansion into endocrinology and aggressive debt reduction.

AMRX Amneal Corp: Price to Earnings Ratio in the range 07/04/2022 - 11/17/2026

Comprehensive metric breakdowns and analytics for Amneal Pharmaceuticals, Inc. (AMRX)

Comprehensive company analysis:Amneal - AMRX
Flagship merchandise of Amneal

Investors are assessing the resilience of Amneal Pharmaceuticals (AMRX), considering the risks of raw material supply chain disruptions from Asia that could destabilize net income. By analyzing the company's historical P/E dynamics, one can determine how many years of current earnings the market is willing to pay to avoid a "value trap" amid an undervalued business valuation in conditions of geopolitical uncertainty.

Key competitors

HLN: Company Value to Net Income|Price to Earnings Ratio KVUE (Kenvue Corp)|VRNA (Verona Pharma Inc.) - Company Value to Net Income|Price to Earnings Ratio Jyong Biotech Limited MENS|Ligand (LGND) - Market Cap to Earnings|PRGO: Price to Earnings Ratio|Alvotech SA - Market Price to Net Income Ratio|LQDA: P/E Multiple|Galapagos Genomics - Company Value to Net Income|ANIP (ANI Pharmaceuticals Inc) - P/E Multiple|Market Cap to Earnings mannkindcorp.com MNKD|Price to Earnings Ratio Amphastar Pharmaceuticals, Inc. (AMPH)|PCRX (Pacira Pharmaceuticals) - Company Value to Net Income|P/E Multiple SPRY (ARS Pharmaceuticals Inc)|Market Price to Net Income Ratio TBPH (Theravance)|AQST - Price to Earnings Ratio|scPharmaceuticals (SCPH) - Price to Earnings Ratio|TECX: P/E Multiple|Price to Earnings Multiple TNXP|Price to Earnings Ratio China SXT Pharmaceuticals, Inc.|EPRX: Company Value to Net Income|P/E Multiple BHST|EXOZ - Market Cap to Earnings|P/E Multiple ORMP (oramed.com)|P/E Multiple enterabio.com ENTX|HYFT - Price to Earnings Ratio|Business Payback Period ABVC BioPharma, Inc ABVC|CPIX: P/E Multiple|Quantum BioPharma Ltd - Company Value to Net Income|Price to Earnings Ratio FGEN|Telomir Pharmaceuticals, Inc. - Market Cap to Net Income|P/E Multiple RANI|SNYR (Synergy CHC) - Company Value to Net Income|Price to Earnings Ratio Rallybio RLYB|Lexaria Bioscience (LEXX) - Market Cap to Earnings|PULM - Price to Earnings Ratio|Business Payback Period Pheton Holdings PTHL|APM (Aptorum) - Price to Earnings Ratio|Lyra Therapeutics, Inc. (LYRA) - P/E Multiple|IBO (impactbiomedinc.com) - P/E Multiple|TNFA (TNF Pharmaceuticals) - Market Price to Net Income Ratio|Price to Earnings Ratio cbdmd.com (YCBD)|Business Payback Period PainReform Ltd|P/E Multiple CYTO (Altamira Therapeutics Ltd.)|Lipella Pharmaceuticals (LIPO) - Market Cap to Earnings|OPTN - Price to Earnings Ratio|Pieris Pharmaceuticals - Market Price to Net Income Ratio|PROC (Procaps Group) - Price to Earnings Ratio|PTPI - Business Payback Period|Price to Earnings Ratio Qilian International Holding Group Limited|SLRN: Company Value to Net Income|Price to Earnings Ratio TFFP (TFF Pharma)